Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma
Metrics: PDF 1388 views | HTML 1127 views | ?
Christos Demosthenous1,*, Jing Jing Han1,*, Mary J. Stenson1, Matthew J. Maurer1, Linda E. Wellik1, Brian Link2, Kristen Hege3, Ahmet Dogan4, Eduardo Sotomayor5, Thomas Witzig1, Mamta Gupta1
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
2Department of Internal Medicine, University of Iowa College of Medicine, IA, USA
3Celgene Corporation, San Francisco, CA, USA
4Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
*These authors have contributed equally to this work
Mamta Gupta, e-mail: firstname.lastname@example.org
Keywords: translation initiation complex, eIF4E, lymphoma, dual mTOR inhibitors, CC214-1
Received: February 11, 2015 Accepted: February 12, 2015 Published: March 20, 2015
Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Over-expression of wild-type eIF4E (eIF4EWT) but not cap-mutant eIF4E (eIF4Ecap mutant) increased the activation of the eIF4F complex. Treatment with the active-site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.